Genenews Selected To Present Late-breaking Abstract At AACR Annual Meeting
Abstract describes six-gene biomarker panel for assessment of current risk for colorectal cancer
TORONTO, CANADA (March 17, 2008):
GeneNews Limited (TSX: GEN), a company focused on developing molecular diagnostic tests derived from a simple blood sample for the early detection of diseases and personalized health management, today announced that its abstract describing the performance of the Company’s six-gene biomarker panel for the assessment of a person’s current risk for colorectal cancer from a blood sample, has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The abstract is entitled “Stratification of colorectal cancer probability using six genes from whole blood.”
“This six gene biomarker set will form the basis of a laboratory developed test (LDT) version of ColonSentry™, which we expect to launch in the third quarter of 2008 through our in-house clinical reference lab located in the Toronto-area,” said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. “We are pleased that AACR has chosen to accept our abstract given the limited number of late-breaking submissions that are accepted and believe that this acceptance also represents further peer-reviewed validation of our proprietary Sentinel Principle technology.”
The following GeneNews abstract will be presented:
Abstract Number LB-214:
“Stratification of colorectal cancer probability using six genes from whole blood.” Clinical Research 2, Poster Section 19, Tuesday, April 15, 2008, 8:00 AM
Forward-Looking Statements
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
